Biktarvy 50 mg/200 mg/25 mg film-coated tablets

Product Information *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 01 June 2021

File name

Biktarvy SmPC XI&IE ( May 2021)_1622532563.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update the nephrotoxicity information (Section 4.4 of the Summary of Product Characteristics [SmPC] and Section 2 of the Patient Information Leaflet [PIL]) 

Administrative updates to the SmPC sections 4.5 and 4.9 for Biktarvy

Updated on 01 June 2021

File name

Biktarvy PIL XI&IE ( May 2021)_1622532452.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 30 April 2021

File name

Biktarvy - SmPC - April 2021 _1619801850.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

To add blister packaging for Biktarvy tablets, 30 and 90 film-coated tablet packs.

Sections of the SmPC updated: 6.3, 6.4, 6.5, 8 and 10
Annex III A:  Outer carton for 30- tablet pack
                     Outer carton for 90- tablet pack
                     Intermediate carton for 90- tablet pack
                     7- tablet blister
                     2- tablet blister
Sections of the PIL updated: 3, 4, 5 and 6

 

Updated on 30 April 2021

File name

Biktarvy PIL - April 2021_1619801680.pdf

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation number

Free text change information supplied by the pharmaceutical company

To add blister packaging for Biktarvy tablets, 30 and 90 film-coated tablet packs.

Sections of the SmPC updated: 6.3, 6.4, 6.5, 8 and 10
Annex III A:  Outer carton for 30- tablet pack
                     Outer carton for 90- tablet pack
                     Intermediate carton for 90- tablet pack
                     7- tablet blister
                     2- tablet blister
Sections of the PIL updated: 3, 4, 5 and 6

 

Updated on 18 December 2020

File name

Biktarvy SmPC - December 2020_1608307142.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Type II variation application, to update the Biktarvy product information with the adverse drug reaction Stevens-Johnson Syndrome (SJS). This variation is a result of the CCDS v6.0 Category 2. The product information has been updated as follows: SmPC section 4.8

 

Updated on 18 December 2020

File name

Biktarvy PIL - December 2020_1608306914.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Type II variation application, to update the Biktarvy product information with the adverse drug reaction Stevens-Johnson Syndrome (SJS). This variation is a result of the CCDS v6.0 Category 2. The product information has been updated as follows:PIL section 4

Updated on 25 November 2020

File name

Biktarvy SmPC - November 2020_1606322901.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 25 November 2020

File name

Biktarvy PIL - November 2020_1606322762.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 25 November 2020

File name

Biktarvy PIL - November 2020_1606322762.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 04 November 2020

File name

Biktarvy SmPC - October 2020_1604494342.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

  •  

Updated on 04 November 2020

File name

Biktarvy PIL - October 2020_1604494240.pdf

Reasons for updating

  • Change to section 3 - how to take/use

Updated on 21 August 2020

File name

Biktarvy SmPC - July 2020_1598020194.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 10 June 2020

File name

Biktarvy SmPC (May 2020)_1591801246.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 10 June 2020

File name

Biktarvy PIL (May 2020)_1591801199.pdf

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 31 March 2020

File name

Biktarvy - SmPC - February 2020_1585671402.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 31 March 2020

File name

Biktarvy - PIL - February 2020_1585671320.pdf

Reasons for updating

  • Change to section 2 - what you need to know - contraindications

Updated on 16 December 2019

File name

Biktarvy SmPC Dec 2019_1576496726.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 15 July 2019

File name

Biktarvy PIL Jun 2019_1563177991.pdf

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 6 - date of revision

Updated on 15 July 2019

File name

Biktarvy SmPC Jun 2019_1563178869.pdf

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

section 2 of the Patient Information Leaflet (PIL) in order to remove the recommendation for caution when methadone is co-administered with Biktarvy

File name

Biktarvy PIL - May 2019_1562683275.pdf

Updated on 09 July 2019

File name

Biktarvy SPC - May 2019_1562683496.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8 of SmPC to include urticaria and angioedema 

Updated on 08 July 2019

File name

Biktarvy PIL - Jul 2019_1562586888.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 08 July 2019

File name

Biktarvy SPC - Jul 2019_1562586690.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8. of the SmPC, specifically tabulated list of adverse reactions to include angioedema and urticarial as additional adverse reactions, following a safety review conducted by Gilead, concluding the causal association of the two adverse reactions with TAF-containing products. 

Updated on 27 May 2019

File name

Biktarvy PIL - Apr 2019_1558825276.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 25 May 2019

File name

Biktarvy SmPC - Apr 2019_1558825516.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Variation submitted to update sections 4.8 and 5.1 of the SmPC with efficacy and safety information based on pooled 96-week data from two randomized, double-blind, active controlled studies GS-US-380-1489 and GS-US-380-1490 in HIV-1 infected, antiretroviral treatment-naïve adults receiving Biktarvy compared with each of the comparator treatment groups (i.e. pooled Biktarvy  (BVY) vs abacavir /dolutegravir /lamivudine and pooled BVY vs dolutegravir + emtricitabine/tenofovir alafenamide).

 

The opportunity was also taken to include an administrative update to the PIL to align the warnings and precautions wording related to potential kidney problems with the warnings and precautions wording in the Odefsey PIL.

Updated on 31 October 2018

File name

Biktarvy SmPC - Oct 2018_1540999148.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 31 August 2018

File name

Biktarvy PIL - Aug 2018_1535716938.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 31 August 2018

File name

Biktarvy SmPC - Aug 2018_1535716977.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 03 July 2018

File name

Biktarvy_SmPC_Jun2018.docx

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 03 July 2018

File name

Biktarvy PIL - Jun2018.pdf

Reasons for updating

  • New PIL for new product